Martin Sjöström Selected Research

Pharmaceutical Preparations

2/2022	TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
1/2022	Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.
1/2022	Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity.
9/2021	Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures.
1/2021	An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer.
1/2021	Proteogenomic Workflow Reveals Molecular Phenotypes Related to Breast Cancer Mammographic Appearance.
1/2021	Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin Sjöström Research Topics

Disease

22	Neoplasms (Cancer) 02/2022 - 05/2014
15	Breast Neoplasms (Breast Cancer) 01/2022 - 04/2013
11	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 11/2017
4	Neoplasm Metastasis (Metastasis) 12/2020 - 01/2015
2	Urinary Bladder Neoplasms (Bladder Cancer) 02/2022 - 01/2021
2	Disease Progression 01/2022 - 01/2016
1	Carcinoma (Carcinomatosis) 02/2022
1	Hypoxia (Hypoxemia) 01/2022
1	Carcinogenesis 01/2022
1	Melanoma (Melanoma, Malignant) 12/2020
1	Lobular Carcinoma 06/2019
1	Lymphatic Metastasis 01/2015

Drug/Important Bio-Agent (IBA)

8	Biomarkers (Surrogate Marker)IBA 09/2021 - 07/2015
7	Pharmaceutical PreparationsIBA 02/2022 - 01/2021
7	Estrogen ReceptorsIBA 01/2021 - 04/2013
5	Phenobarbital (Luminal)FDA Link 01/2022 - 10/2017
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2015
4	GTP-Binding Proteins (G-Protein)IBA 01/2020 - 04/2013
3	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 06/2019
3	Tamoxifen FDA LinkGeneric 01/2020 - 04/2013
2	Immunoconjugates (Immunoconjugate)IBA 02/2022 - 01/2021
2	enfortumab vedotinIBA 02/2022 - 01/2021
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 11/2021
2	AndrogensIBA 01/2022 - 11/2021
2	AntigensIBA 01/2021 - 12/2020
2	Progesterone Receptors (Progesterone Receptor)IBA 06/2019 - 05/2014
1	sacituzumab govitecanIBA 02/2022
1	PanobinostatIBA 01/2022
1	Dasatinib (BMS 354825)FDA Link 01/2022
1	enzalutamideIBA 01/2022
1	Proto-Oncogene Proteins c-etsIBA 01/2022
1	Serine Proteases (Serine Protease)IBA 01/2022
1	AutoantibodiesIBA 12/2020
1	EpitopesIBA 12/2020
1	hydrogen sulfite (bisulfite)IBA 01/2020
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2020
1	Messenger RNA (mRNA)IBA 11/2017
1	ErbB Receptors (EGF Receptor)IBA 10/2017
1	Aldehyde DehydrogenaseIBA 12/2015
1	Peptides (Polypeptides)IBA 07/2015
1	ProteomeIBA 07/2015
1	GlycopeptidesIBA 07/2015
1	Glycoproteins (Glycoprotein)IBA 01/2015
1	Indicators and Reagents (Reagents)IBA 04/2013

Therapy/Procedure

8	Therapeutics 01/2022 - 01/2015
8	Radiotherapy 01/2022 - 10/2017
7	Segmental Mastectomy (Lumpectomy) 01/2022 - 10/2017
5	Castration 11/2021 - 11/2017
5	Adjuvant Radiotherapy 01/2021 - 10/2017
2	Immunotherapy 12/2020 - 01/2019
1	Aftercare (After-Treatment) 11/2021